Apar Ganti
Associate Director for Clinical Research, Fred & Pamela Buffett Cancer Center · University of Nebraska Medical Center College of Medicine
Credentials: · · · · · ·
History
2001–2003- 1996–1999
Research
JAMA Oncology · 2021 · First of 5 authors · 683 citations
Targeting the EGFR signaling pathway in cancer therapy
Review · Expert Opinion on Therapeutic Targets · 2012 · 683 citations
Review · Journal of the National Comprehensive Cancer Network · 2010 · 522 citations
- SB
43 papers
- AP
25 papers · 25 as a resident
17 papers · 2 as a fellow
- KT
12 papers · 1 as a resident
12 papers
11 papers · 10 as a fellow
- SM
9 papers
9 papers
Grants
- 1997–2027
Buffett Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $2.5M · University of Nebraska Medical Center
- 2020–2024
Role of MUC5AC in Promoting CNS Metastasis in Non-Small Cell Lung Cancer
Department of Veterans Affairs · I01
Contact PI · Omaha Va Medical Center
Clinical trials
- 2021–2025
Principal investigator · Terminated · Phase 1, Phase 2
University of Nebraska
- 2020–2021
A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC
Principal investigator · Terminated · Phase 1
University of Nebraska
- 2015–2021
Docetaxel and Capecitabine With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Principal investigator · Terminated · Phase 2
University of Nebraska
- 2009–2018
Principal investigator · Completed · Phase 1
University of Nebraska
Honors
FASCO